

Impact of glycemic status on longitudinal cognitive performance in men with and without HIV infection

Jingyan Yang^{a,b}, Lisa P. Jacobson^c, James T. Becker^d, Andrew Levine^e, Eileen M. Martin^f, Cynthia A. Munro^g, Frank J. Palella^h, Jordan E. Lakeⁱ, Ned C. Sacktor^g and Todd T. Brown^j

Objectives: To determine the relationship between glycemic status and cognitive performance in men living with HIV (MLWH) and without HIV infection.

Design: A prospective HIV/AIDS cohort study in four US cities between 1999 and 2016.

Methods: Glycemic status was categorized as normal glucose, impaired fasting glucose, controlled diabetes mellitus and uncontrolled diabetes mellitus at each semi-annual visit. Cognitive performance was evaluated using nine neuropsychological tests which measure attention, constructional ability, verbal learning, executive functioning, memory and psychomotor speed. Linear mixed models were used to assess the association between glycemic status and cognition.

Results: Overall, 900 MLWH and 1149 men without HIV were included. MLWH had significantly more person-visits with impaired fasting glucose (52.1 vs. 47.9%) and controlled diabetes mellitus (58.2 vs. 41.8%) than men without HIV ($P < 0.05$). Compared with men with normal glucose, men with diabetes mellitus had significantly poorer performance on psychomotor speed, executive function and verbal learning (all $P < 0.05$). There was no difference in cognition by HIV serostatus. The largest effect was observed in individuals with uncontrolled diabetes mellitus throughout the study period, equivalent to 16.5 and 13.4 years of aging on psychomotor speed and executive function, respectively, the effect of which remained significant after adjusting for HIV-related risk factors. Lower CD4⁺ nadir was also associated with worse cognitive performance.

Conclusion: Abnormalities in glucose metabolism were more common among MLWH than men without HIV and were related to impaired cognitive performance. Metabolic status, along with advanced age and previous immunosuppression, may be important predictors of cognition in the modern antiretroviral therapy era.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

AIDS 2018, **32**:1849–1860

Keywords: cognition, diabetes mellitus, HIV-1, male, neuropsychological tests

^aDepartment of Epidemiology, Mailman School of Public Health, Columbia University, ^bDepartment of Orthopedic Surgery, Hospital for Special Surgery, New York, New York, ^cDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, ^dDepartment of Psychology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, ^eDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, ^fDepartment of Psychiatry, Rush University Medical Center, Chicago, Illinois, ^gDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, ^hDepartment of Medicine, Northwestern University, Chicago, Illinois, ⁱDepartment of Internal Medicine, McGovern Medical School, University of Texas, Houston, Texas, and ^jDivision of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA.

Correspondence to Todd T. Brown, MD, PhD, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, 1830 East Monument Street, Suite 333, Baltimore, MD 21287, USA.

E-mail: tbrown27@jhmi.edu

Received: 15 December 2017; revised: 28 February 2018; accepted: 12 March 2018.

DOI:10.1097/QAD.0000000000001842

Introduction

The use of combination antiretroviral therapy (cART) has transformed HIV infection into a chronic illness and has markedly extended survival among people living with HIV (PLWH), often into old age [1]. However, the effect of cART on HIV-associated cognitive impairment is modest [2–4]. The prevalence of cognitive dysfunction among PLWH continues to be high [2,5–7], and the cause is not clear. Hypotheses include, but are not limited to, immune system integrity and inadequate control of persistent central nervous system HIV viral replication [8,9]. In addition, chronic non-AIDS comorbidities such as impaired glucose regulation, which is common among PLWH [10], may also play an important role in the pathogenesis of cognitive dysfunction [11].

In the general population, type 2 diabetes mellitus (T2DM) has been associated with impairment in numerous cognitive domains [12–17]. T2DM predominantly affects hippocampal-based declarative memory performance and attention, but psychomotor speed and executive functioning are also affected [13,18]. The magnitude of cognitive decline depends largely on the duration of T2DM, glycemic control and antidiabetic agent use [19–25]. It has been reported that a 1% higher glycated hemoglobin (HbA1c) value is associated with significantly lower performance on psychomotor speed executive functioning and memory [26].

In PLWH, the prevalence of T2DM is up to 14% [10], compared with 9.4% in the US population [27] and associations between glycemic status and cognition have also been reported [28]. For example, in a prospective cohort enriched with older HIV-infected individuals, diabetes was associated with a five-fold increased odds of HIV-associated dementia compared with people without diabetes and this association remained significant after multivariable adjustment [29]. In the Women's Interagency HIV Study, greater insulin resistance was associated with poorer performance on Symbol Digit Modalities Test (SDMT), on Stroop Color-Naming and on Stroop Interference in unadjusted analyses [30]. Similar results were found using adjusted models in a more recent study of the same cohort [31]. In addition, the authors reported that women with T2DM had worse performance on measure of psychomotor speed and manual dexterity testing than women without T2DM [31].

Despite evidence suggesting that glycemic status is associated with cognition in PLWH and without HIV, previous cross-sectional studies were limited in their ability to investigate longitudinal glycemic status with regard to trajectories of cognitive function over time [29,30,32]. In some cases, assessment of cognitive domains was not comprehensive [33,34] and glycemic status was not adequately characterized [30,31]. The purpose of the current study was to determine the

longitudinal relationship between glycemic status and cognition using data from Multicenter AIDS Cohort Study (MACS), one of the largest ongoing cohorts of the natural and treated history of HIV among gay/bisexual men. The MACS has followed a neuropsychological subcohort for over 29 years, allowing for determination of the neurological and neurocognitive consequences of HIV over time [35]. We hypothesized that: glycemic status is associated with cognitive performance among men living with HIV (MLWH) and without HIV; the magnitude of this effect varies by cognitive domains; the duration of T2DM is associated with accelerated cognitive decline; and HIV-specific risk factors affect cognition in MLWH.

Methods

Study participants

A total of 6972 MACS participants have been recruited from four sites: Baltimore/Washington DC, Chicago, Los Angeles and Pittsburgh over three waves of enrollment (4954 men were enrolled in 1984–1985, 668 men in 1987–1991 and 1350 men in 2001–2003) [36,37]. Eligibility criteria and follow-up procedures for the MACS have been described in detail previously [36,38]. The current study included all participants who were active in the MACS between April 1999 and Oct 2016. Individuals whose primary language was not English or had any of the following conditions: a major neurologic or psychiatric illness, clinical stroke, dementia, learning disability, major head injury or brain opportunistic infection were excluded from the analysis. In addition, 72 men who became HIV infected during follow-up were excluded. The MACS protocol was approved by the institutional review board at each site. Informed consent was obtained from all participants.

During semiannual visits, interviewer-administrated questionnaires were completed. Clinical assessment and biological specimens were obtained for laboratory determination of HIV/AIDS disease biomarkers. Reactive ELISAs, which were confirmed by western blot tests, were used to determine HIV serostatus. Plasma HIV-1 RNA levels were measured using the Roche Ultrasensitive RNA PCR assay (Hoffman-LaRoche, Nutley, New Jersey, USA) with a lower detection limit of 50 copies/ml. T-lymphocyte cell subset numbers and percentages were quantified using standardized flow cytometry [39]. For the purpose of analysis, the index visit was defined as the first visit at which participants had both metabolic assessment and neuropsychological evaluation.

Impaired fasting glucose and type 2 diabetes mellitus assessment

Fasting serum glucose was measured at each semiannual visit beginning in April 1999, under the fasting protocol,

which has been described previously [10]. Men were categorized as having impaired fasting glucose (IFG) if they had a fasting blood glucose level between 100 and 125 mg/dl. Self-reported T2DM was assessed using the following questions: 'Have you seen a doctor or other medical practitioner for any condition since your last visit? If yes, was there a diagnosis for your condition?' Current T2DM medication use was determined from a report of all medications used since the previous visit. Men were categorized as having T2DM if they: self-reported T2DM as a medical condition or took antidiabetic medications or fasting blood glucose level at least 126 mg/dl for two consecutive visits. T2DM was further dichotomized as controlled T2DM and uncontrolled T2DM if HbA1c less than 7.5% and HbA1c at least 7.5% confirmed at two consecutive visits, respectively. Men who were not categorized in any of the groups above were considered to have normal glucose level. Glycemic status was assessed for each individual at each follow-up visit.

Neuropsychological evaluation

Primary neurocognitive tests were the SDMT [40] and the Trail Making Test (TMT) Part A and B [41]. Part A of the TMT is a test of attention, motor speed and visuospatial tracking [34]. Part B of the TMT has all of the cognitive demands of TMT Part A, with an addition of a set-shifting component, which tests executive functioning. The TMT is sensitive to aging effects among the elderly [42]. The SDMT evaluates psychomotor speed, associative learning and incidental learning, and has demonstrated reliability independent of age, sex and socioeconomic status [43]. The full neuropsychological battery included the Grooved pegboard (nondominant hand) (GPN), a sensitive measure of manual dexterity [44]; Rey Auditory Verbal Learning Test (RAVLT) [45], immediate and delayed recall trials, assessing auditory learning and memory; Rey-Osterrieth Complex Figure (RCF) [46], immediate and delayed recall trials, assessing visual learning memory; and the Stroop Test-Interference Trial (SIT) [47], a measure of response inhibition, considered an executive function. The TMT and SDMT have been administered at each semiannual visit since 1 October 1991, and the full battery of neuropsychological tests every 2 years since 1 October 2005. These nine tasks were selected to be sensitive to most major areas of cognitive functioning. The validity/reliability of the above neuropsychological tests among PLWH have been reported in the previous studies [48,49].

Other covariates and risk factors

Age (<40, 40–50 and >50 years old), race (white, Black and other) and education (college degree versus less than college) were demographics selected. Depressive symptoms were defined using the Center for Epidemiologic Studies Depression Scale more than 16; hypertension was defined as DBP at least 90 or SBP at least 140 or (self-reported/clinical diagnosis of hypertension and use of

medications); hypercholesterolemia was defined as fasting total cholesterol (TC) at least 200 mg/dl or LDL at least 130 mg/dl or HDL less than 40 mg/dl or triglycerides at least 150 mg/dl or use of lipid-lowering medications with self-reported/clinical diagnosis in the past; hepatitis C virus (HCV) infection was considered present if a participant's serum HCV antibody and HCV RNA (COBAS AmpliPrep TaqMan HCV Assay) were positive; intravenous drug users (IVDU) and cocaine use were determined based on questions 'Took/used drugs with a needle since last visit?' and 'Used crack or any form of cocaine since last visit?', respectively; BMI was calculated using $\text{weight (kg)}/[\text{height (m)}]^2$: less than 18.5 is considered underweight, 18.5 to less than 25 is normal, 25.0 to less than 30 is overweight and at least 30.0 is obese. Participants were asked if they currently smoke at each visit and former smokers would be those who answered yes and then no at a later visit. All covariates were updated by participants at each follow-up visit.

Statistical analysis

Comparisons of baseline characteristics, stratified by HIV serostatus, were performed using Student *t* tests for normally distributed continuous variables, Wilcoxon rank-sum tests for variables with skewed distributions and chi-square tests for categorical data. All neuropsychological test scores were transformed and summarized as *z*-scores with adjustment for learning effect, age and education. A higher *z*-score indicated better cognitive performance.

The association of glycemic status with cognition was examined using linear mixed models with random intercept allowed. This approach assessed within-individual changes in neuropsychological test scores from baseline to the end of the study period, accounting for within-person correlations. The analysis used all person-visits for three primary outcomes: SDMT, TMT-A and TMT-B, and six secondary outcomes from the tests in the full battery of neuropsychological tests. For the initial models, the performance of each neuropsychological test was a function of follow-up time, glycemic status, HIV serostatus and potential confounders. The interaction of *follow-up time*glycemic status* was then added to examine if there was an association of glycemic status and changes in cognitive performance over time. To assess the effect of cumulative exposure to glycemic impairment on cognition, the diabetes mellitus group was further categorized according to the percentage of time under observation during which diabetes mellitus was uncontrolled. This analysis used the same linear mixed model format from the initial model. Lastly, subgroup analysis was performed among MLWH to examine the role of nadir CD4⁺ T-cell count (<200, 200–500, >500 cells/ μ l), undetectable HIV RNA and time on cART (in years), with the same covariate adjustments from the initial model. Analyses were performed using Stata 14.0 SE (StataCorp, College Station, Texas, USA).

Table 1. Demographic characteristics of study population by HIV serostatus at baseline.

Characteristics	HIV uninfected N = 900	HIV infected N = 1149	P value
Number of person-visits, median (IQR)	11 (5, 18)	10 (5, 18)	<0.001
Follow-up time (years), mean (SD)	6.8 (4.4)	6.8 (4.5)	0.42
Age (%)			
<40 years	33.1	45.0	
40–50 years	36.9	39.8	
>50 years	30.0	15.2	<0.001
Race (%)			
White	64.9	51.7	
Black	28.2	37.1	
Others	6.9	11.2	<0.001
College education (%)	79.3	69.4	<0.001
Depressive symptoms (%)	23.9	30.1	0.002
CD4 ⁺ T-cell count nadir (cells/ μ l, %)			
<200	–	30.8	
200–500	–	51.6	
\geq 500	–	17.6	–
Undetectable HIV-1 RNA (copies, %)	–	57.0	–
Hypertension (%)	30.7	26.5	0.040
Hypercholesterolemia (%)	63.9	76.6	<0.001
HCV infection (%)	5.9	9.9	0.001
Intravenous drug users (%)	1.8	2.2	0.52
Cocaine use (%)	13.4	17.8	0.007
BMI (%)			
Underweight or normal	41.0	50.0	
Overweight	38.0	37.5	
Obese	21.0	12.5	<0.001
Smoking status (%)			
Never	28.4	27.2	
Former	37.3	31.6	
Current	34.2	41.2	0.003
Glucose, median (IQR) (mg/dl)	91 (84, 99)	92 (85, 100)	0.85
HbA1c, median (IQR) (mmol/mol)	5.2 (4.9, 5.5)	5.1 (4.7, 5.5)	<0.001
Glycemia status (%)			
Normal	75.7	72.4	
IFG	17.3	19.7	
Controlled DM	4.7	6.8	
Uncontrolled DM	2.3	1.1	0.015
Diabetic medication (%)	3.2	3.7	0.53
Diabetes duration, mean (SD) (year)	6.9 (4.4)	7.4 (4.9)	0.18

DM, diabetes mellitus; HbA1c, higher glycated hemoglobin; IFG, impaired fasting glucose; IQR, interquartile range.

Results

Demographic characteristics

In total, 1149 MLWH and 900 men without HIV were included, with a mean follow-up of 13 (\pm 4) years. Compared with men without HIV, MLWH tended to be younger, were more likely to be Black, obese, current smokers, cocaine users, infected with HCV, to have reported hypertension, depressive symptoms, hypercholesterolemia, but less likely to have college education (Table 1). At baseline, MLWH were also more likely to have abnormalities in glucose metabolism than the men without HIV, though no statistically significant differences in IVDU status, glucose level, use of diabetes mellitus medications and diabetes mellitus duration were found by HIV serostatus.

Cognitive performance test results

At baseline, except for TMT-A, RAV-sum of learning trails, RAV-delayed recall and GPN, MLWH

demonstrated significantly poorer performance on all neuropsychological tests than men without HIV (Table 2). Longitudinally, linear mixed models indicated that factors associated with lower performance in all nine neuropsychological tests included being Black, the presence of depressive symptoms, IVDU and current smoking, whereas other risk factors including education, cocaine use, hypercholesterolemia, HCV infection, BMI and older age differed in their associations across cognitive domains (Table 3).

Psychomotor speed and attention

TMT-A, SDMT and GPN primarily evaluate psychomotor speed and attention (Table 3). Men with uncontrolled T2DM had significantly worse performance on TMT-A (Coef. = -0.137 , $P < 0.001$) and SDMT (Coef. = -0.121 , $P = 0.001$) compared with men with normal glucose, regardless of HIV serostatus, equivalent to the effect of 3.9 and 8.8 years of aging (derived from coefficient estimation of age parameter) on psychomotor

Table 2. Unadjusted performance of neuropsychological tests by HIV serostatus at baseline.

NP tests	HIV-uninfected mean (SD)	HIV-infected mean (SD)	P value
Psychomotor speed, attention			
Symbol Digital Test ^a	53.7 (12.8)	51.5 (12.4)	<0.001
Trail Making Test Part A ^b	25.8 (10.3)	26.3 (11.3)	0.25
Executive functioning			
Trail Making Test Part B ^b	59.1 (31.2)	64.9 (35.4)	<0.001
Stroop-interference (s) ^b	109.4 (29.0)	114.9 (29.5)	0.004
Verbal learning and memory ^a			
RAV-sum of learning trails	49.7 (10.8)	49.7 (10.6)	0.95
RAV-delayed recall	9.8 (3.4)	9.8 (3.3)	0.91
RCF-copy	32.6 (4.3)	31.5 (4.9)	<0.001
RCF-delayed recall	21.1 (7.6)	19.5 (7.8)	0.001
Motor slowing			
Grooved Pegboard-nondominant hand ^b	73.8 (16.7)	74.1 (17.4)	0.79

RAV, Rey Auditory Verbal; RCF, Rey–Osterrieth Complex Figure.

^aHigher score indicates better cognitive performance.

^bTime-related neuropsychological tests: less time indicates better cognitive performance.

speed and attention, respectively. Men with controlled T2DM (Coef. = -0.219 , $P < 0.001$) and IFG (Coef. = -0.027 , $P = 0.014$) also had worse neuropsychological scores on GPN and SDMT, respectively, than men with normal glucose. However, no associations were observed on the following: IFG on both TMT-A and GPN, controlled T2DM on SDMT and TMT-A and uncontrolled diabetes mellitus on GPN. Current smoking, Black race and IVDU were associated with worse performance, whereas being overweight/obese seemed to have a protective effect on cognition regardless of HIV serostatus. Further analysis with the interaction has shown a significant cognitive decline in IFG, controlled and uncontrolled T2DM compared with normal glucose on TMT-A. A similar pattern was also found among both controlled and uncontrolled T2DM compared with normal glucose on SDMT and GPN (data not shown).

Executive function

SIT and TMT-B are considered measures of executive function (Table 3). Only men with uncontrolled diabetes mellitus (Coef. = -0.077 , $P = 0.048$) had significantly poorer executive function, measured by TMT-B, than men with normal glucose, an equivalent effect of 1.8 years of aging. Worse performance was observed for TMT-B but not for SIT in association with current smoking and Black race. Significant cognitive decline over time was observed in both controlled and uncontrolled T2DM compared with normal glucose on TMT-B.

Verbal learning and memory

RAVLT (Sum of Learning Trails & Delayed Recall) and RCF (Copy & Delayed Recall) assess verbal learning and visuospatial memory (Table 3). Only men with controlled diabetes mellitus (Coef. = -0.114 , $P = 0.008$) had worse cognitive performance on RAVLT (Sum of Learning Trails) than men with normal glucose, a difference similar to 9 years of aging on verbal learning and memory, though no significant associations were observed on RAVLT (Delayed recall) or RCF. Current smoking status,

Black race and IVDU were associated with worse cognitive performance, whereas hypercholesterolemia showed a protective effect on cognition.

Type 2 diabetes mellitus disease duration

Among men with diabetes mellitus, disease duration was further categorized as the percentage of time with diabetes mellitus being uncontrolled over the study period (0, 0 to <30, 30 to <70, 70 to <100, 100%), according to quintiles. The impact of glycemic status on cognition was predominantly seen among men who had uncontrolled T2DM more than 70% of the time (Table 4). Specifically, this effect is equivalent to 16.5 years of aging on psychomotor speed and attention (tested by TMT-A, Coef. = -0.726 , $P = 0.001$) as well as 13.4 years of aging on executive function (tested by TMT-B, Coef. = -0.676 , $P = 0.003$).

Analysis restricted to men living with HIV

Subgroup analysis was performed in regard to three primary neuropsychological tests. With additional HIV-related covariates adjusted, the effect of uncontrolled T2DM remained significant on all three tests: SDMT (Coef. = -0.156 , $P = 0.005$), TMT-A (Coef. = -0.138 , $P = 0.018$) and TMT-B (Coef. = -0.123 , $P = 0.039$) (Table 5). Moreover, men with nadir CD4⁺ T-cell counts below 200 cells/ μ l (Coef. = -0.157 , $P = 0.006$) had significantly worse cognitive performance on TMT-A than men with counts above 500 cells/ μ l. However, neither having undetectable HIV-1 RNA nor length of cART showed a significant relationship with cognition.

Discussion

Our data support the hypothesis that abnormalities in glucose metabolism are associated with neuropsychological dysfunction among MLWH and without HIV. Greater cognitive impairment was correlated with poor

Table 3 (continued)

Factors	Verbal learning and memory			
	RAV-sum of learning trails Coef.	RAV-delayed recall Coef.	RFC-delayed recall Coef.	RFC-copy Coef.
HIV infection	-0.037 (-0.12, 0.05)	-0.075 (-0.16, 0.01)	0.077 (-0.01, 0.17)	-0.039 (-0.15, 0.08)
Glycemic status				
Normal	Ref	Ref	Ref	Ref
IFG	-0.016 (-0.07, 0.04)	-0.047 (-0.10, 0.01)	-0.043 (-0.10, 0.01)	-0.027 (-0.10, 0.05)
Controlled DM	-0.114** (-0.20, -0.03)	-0.063 (-0.15, 0.02)	-0.014 (-0.10, 0.07)	-0.107 (-0.22, 0.01)
Uncontrolled DM	-0.094 (-0.25, 0.06)	0.102 (-0.06, 0.26)	0.048 (-0.11, 0.20)	-0.049 (-0.27, 0.17)
Hypertension	-0.047 (-0.10, 0.01)	0.002 (-0.05, 0.06)	-0.022 (-0.08, 0.03)	-0.030 (-0.11, 0.05)
HCV infection	-0.034 (-0.18, 0.11)	-0.006 (-0.15, 0.14)	-0.102 (-0.25, 0.05)	0.217*** (0.02, 0.41)
IDU	-0.173 (-0.36, 0.01)	-0.249** (-0.44, -0.06)	-0.026 (-0.21, 0.16)	-0.156 (-0.41, 0.10)
Cocaine use	0.047 (-0.03, 0.12)	0.050 (-0.03, 0.13)	-0.020 (-0.10, 0.06)	-0.040 (-0.15, 0.07)
Hypercholesterolemia	0.011 (-0.04, 0.07)	-0.024 (-0.08, 0.03)	0.057*** (0.00, 0.11)	0.083*** (0.00, 0.16)
BMI				
Underweight/normal	Ref	Ref	Ref	Ref
Overweight	0.021 (-0.04, 0.08)	0.022 (-0.04, 0.08)	-0.019 (-0.08, 0.04)	0.002 (-0.08, 0.09)
Obesity	0.053 (-0.03, 0.14)	0.016 (-0.07, 0.10)	0.039 (-0.05, 0.13)	0.085 (-0.03, 0.20)
Depression	-0.051 (-0.11, 0.00)	-0.092** (-0.15, -0.04)	-0.019 (-0.07, 0.04)	-0.025 (-0.10, 0.05)
Smoking status				
Never	Ref	Ref	Ref	Ref
Former	-0.061 (-0.16, 0.03)	-0.061 (-0.15, 0.03)	-0.078 (-0.17, 0.02)	0.008 (-0.12, 0.13)
Current	-0.122*** (-0.22, -0.02)	-0.071 (-0.17, 0.03)	-0.137** (-0.24, -0.04)	0.030 (-0.10, 0.16)
New cohort	0.034 (-0.01, 0.08)	0.032 (-0.01, 0.07)	-0.070** (-0.11, -0.03)	-0.104* (-0.16, -0.05)

CI, confidence interval; DM, diabetes mellitus; GP, grooved pegboard; HCV, hepatitis C virus; IFG, impaired fasting glucose; RAV, Rey Auditory Verbal; RCF, Rey-Osterrieth Complex Figure; SDMT, Symbol Digit Modalities Test; TMT-A, Trail Making Test Part A; TMT-B, Trail Making Test Part B.

^aWe had 2049 men contributed to the analysis of three primary NP tests and 1617 men had information on the full battery of neuropsychological tests.

^bAll the neuropsychological tests were modeled using z-scores and higher z-scores indicated better cognitive performance.

* <0.001.

** <0.01.

*** <0.05.

Table 4. Relationship between duration of type 2 diabetes mellitus and cognition on three primary neuropsychological tests among men with diabetes mellitus, results from linear mixed model^{a,b}.

Factors	SDMT Coef. 95% CI	TMT-A Coef. 95% CI	TMT-B Coef. 95% CI
Time since baseline (years)	-0.014* (-0.02, -0.01)	-0.010* (-0.01, -0.00)	-0.015* (-0.02, -0.01)
Age			
40 years	Ref	Ref	Ref
40–50 years	-0.166 (-0.36, 0.03)	-0.261** (-0.44, -0.08)	-0.247** (-0.43, -0.06)
≥50 years	-0.438* (-0.67, -0.21)	-0.712* (-0.93, -0.49)	-0.818* (-1.04, -0.60)
Glycemic status			
Controlled DM all the time	Ref	Ref	Ref
Uncontrolled DM time <30%	0.004 (-0.24, 0.25)	-0.043 (-0.27, 0.19)	0.016 (-0.22, 0.25)
Uncontrolled DM time 30–70%	-0.051 (-0.34, 0.23)	0.101 (-0.17, 0.37)	0.119 (-0.15, 0.39)
Uncontrolled DM time >70%	-0.140 (-0.55, 0.27)	-0.098 (-0.49, 0.29)	0.024 (-0.37, 0.42)
Uncontrolled DM all the time	-0.285 (-0.75, 0.18)	-0.726** (-1.17, -0.28)	-0.676** (-1.13, -0.22)
HIV	-0.196*** (-0.36, -0.03)	0.080 (-0.08, 0.24)	-0.047 (-0.21, 0.11)

CI, confidence interval; DM, diabetes mellitus; HCV, hepatitis C virus; IVDU, intravenous drug users; SDMT, Symbol Digit Modalities Test; TMT-A, Trail Making Test Part A; TMT-B, Trail Making Test Part B.

^aAll models have adjusted for race, college education, depression, hypertension, HCV infection, smoking status, BMI, IVDU, cocaine use, hypercholesterolemia, cohort effect and learning effect.

^bHigher score indicated better cognitive performance.

* < 0.001.

** < 0.01.

*** < 0.05.

glycemic control and longer duration of T2DM. In the current study, T2DM was associated with cognitive performance on all the domains. IFG affected psychomotor speed/attention but had a less profound impact on cognition compared with T2DM. Of the nine cognitive tests, the TMT and SDMT appeared to be affected most, demonstrating an increased risk of psychomotor inefficiency, attention deficits and visuospatial tracking problems. Moreover, our results indicate a significant association between longer T2DM duration

and cognitive dysfunction, suggesting that optimization of glycemic control and management of vascular disease risk factors may improve cognitive performance.

Although the affected cognitive domains differ across studies, the magnitude of observed impairment reported in people without HIV in general support our findings [50–56]. Specifically, a systematic review reported that memory, processing speed and cognitive flexibility were most consistently affected by diabetes across studies [57].

Table 5. Relationship between glycemic status and cognition on three primary neuropsychological tests in HIV infected men, results from linear mixed model^a.

Factors	SDMT Coef. 95% CI	TMT-A Coef. 95% CI	TMT-B Coef. 95% CI
Time since baseline (years)	-0.010 (-0.02, 0.00)	0.006 (-0.00, 0.02)	0.008 (-0.00, 0.02)
Age			
40 years	Ref	Ref	Ref
40–50 years	-0.034 (-0.17, 0.10)	-0.202* (-0.33, -0.08)	-0.211* (-0.34, -0.09)
≥50 years	-0.237** (-0.42, -0.05)	-0.621*** (-0.79, -0.45)	-0.704*** (-0.87, -0.53)
Glycemic status			
Normal	Ref	Ref	Ref
IFG	-0.027 (-0.06, 0.00)	-0.019 (-0.05, 0.01)	-0.024 (-0.06, 0.01)
Controlled DM	0.052 (-0.00, 0.11)	-0.002 (-0.06, 0.06)	0.024 (-0.03, 0.08)
Uncontrolled DM	-0.156* (-0.26, -0.05)	-0.138** (-0.25, -0.02)	-0.123** (-0.24, -0.01)
Nadir CD4 ⁺ T-cell count (cells/μl)			
>500	Ref	Ref	Ref
200–500	0.047 (-0.03, 0.12)	-0.047 (-0.12, 0.03)	0.062 (-0.01, 0.14)
<200	0.073 (-0.04, 0.18)	-0.157* (-0.27, -0.05)	0.010 (-0.10, 0.12)
Undetectable HIV RNA	-0.031 (-0.07, 0.01)	-0.014 (-0.05, 0.02)	0.020 (-0.02, 0.06)
Time on cART (years)	0.010 (-0.00, 0.02)	-0.005 (-0.02, 0.01)	-0.010 (-0.02, 0.00)

CI, confidence interval; cART, combination antiretroviral therapy; DM, diabetes mellitus; HCV, hepatitis C virus; IVDU, intravenous drug users; SDMT, Symbol Digit Modalities Test; TMT-A, Trail Making Test Part A; TMT-B, Trail Making Test Part B.

^aAll models have adjusted for race, college education, depression, hypertension, HCV infection, smoking status, BMI, IVDU, cocaine use, hypercholesterolemia, cohort effect and learning effect.

* < 0.01.

** < 0.05.

*** < 0.001.

Among PLWH, increasing insulin resistance negatively affected attention and recognition among women after multivariable adjustment [31].

We also found that duration of T2DM was a strong predictor of cognitive performance, which is consistent with previous studies [20,21,58,59]. A population-based case-control study reported that for participants with a duration of diabetes mellitus for 10 years or longer, their odds of having mild cognitive impairment were significantly elevated, 1.8 fold greater, compared with persons with duration of diabetes mellitus less than 10 years [59]. Similarly, community-dwelling elderly individuals in the highest HbA1c tertile were found to have significantly poorer overall cognition, semantic categorization and executive functioning, whereas such an association was not revealed in the lowest HbA1c tertile, which highlighted the importance of glycemic control in reducing the risk of cognitive decline [22].

In the current study, IFG appeared to be less related than T2DM to cognition, as only mild impairment was observed on psychomotor speed among people with IFG, which has been seen in other studies [60,61]. However, associations reported between IFG and cognition have varied in the literature [62–65]. A pooled cohort analysis that included 8447 individuals from the general population reported that neither elevated fasting glucose levels nor insulin resistance was associated with executive function and memory in older people without a history of diabetes mellitus, whereas individuals with diabetes mellitus were noted to have cognitive decline [66]. In contrast, an analysis from a 4-year study of postmenopausal women reported that IFG increased the risk of developing cognitive dysfunction approximately two fold [67]. Hence, future studies are warranted to investigate whether there are thresholds for effects of dysglycemia on cognition.

We found that HIV stage of disease-related factors such as CD4⁺ nadir were more informative than HIV serostatus regarding cognition in the cART era. A prospective cohort study that consisted of 1525 PLWH demonstrated that the odds of neurocognitive impairment were reduced by 10% for every 5-U increase in square-root CD4⁺ nadir [68]. Heaton *et al.* [69] compared the incidence and characteristics of HIV-associated neurocognitive disorders before and during the cART era and found that low nadir CD4⁺ was associated with neurocognitive dysfunction in both eras, whereas duration of HIV infection and viral suppression predicted impairment only before the cART era, a finding corroborative of our data. These findings support the importance of early cART initiation for disease avoidance, which may help preserve cognition in the long term.

Impaired glucose regulation plays a crucial role in the pathogenesis of cognitive decline, along with vascular risk

factors, socioeconomic and lifestyle factors and depression. Several studies have demonstrated that prediabetes mellitus stage leads to a higher incidence of cognitive impairment [70,71] or dementia [58,72] and T2DM increases the incidence of vascular [73–75] and Alzheimer dementia [75–77]. Increased amyloid processing in the setting of hyperglycemia has been proposed as an underlying mechanism [78]. Other potential mechanisms include increased formation of advanced glycation end products, diacylglycerol activation of protein kinase C and increased glucose shunting in the hexosamine pathway of hyperglycemia, which have been shown to alter function in other organs, but whether similar effects occur in the brain is unclear [79–81].

Multifactorial treatment approaches that target shared causes of diverse vascular disease risk factors, together with lifestyle changes (i.e. weight control, nutrition education) [82,83], may be necessary to prevent cognitive decline. A review has recommended that lifestyle intervention in middle-aged persons should be implemented along with medication for glycemic control to prevent cognitive decline [84]. For persons with a long-standing T2DM, maintaining good glycemic control may modulate the effect of diabetes mellitus on cognition.

To our knowledge, this report represents the largest and most comprehensive evaluation to date of the relationship between glycemic status and cognitive function among MLWH and without HIV. Strengths of our study are its prospective design and long follow-up period with repeated measurement of cognitive function using a sensitive test battery and repeated measures of covariates that allowed us to adjust for a broad array of potential confounders. Our study had several limitations. First, the MACS cohort includes only male participants; additional studies are needed to determine if similar results are observed in women with and without HIV. As multiple, inter-related factors contribute to cognitive performance, understanding the causal pathway of T2DM to cognitive impairment warrants future studies. Further, survivorship bias may have existed in the cohort; some MACS participants have been studied for more than 20 years, whereas those who suffered from more severe HIV-related comorbidities may have been more likely to have dropped out. Lastly, the prevalence of T2DM was high in our cohort, possibly due to extensive ART treatment experience, especially exposure to toxic older ART drugs, and more prolonged untreated HIV infection prior to ART initiation. The generalizability of our results to other cohorts with less treatment experience and shorter HIV infection duration is unclear.

In conclusion, abnormal glucose regulation is associated with worse cognitive performance among both MLWH and without HIV. Glucose-mediated processes and duration of diabetic disease appear to be crucial, and therefore optimization of glycemic control appears to be

an important goal for the maintenance of cognitive performance, along with control of other chronic vascular disease risk factors and lifestyle changes. The optimal timing of interventions aimed at improvements in glycemic control cannot be ascertained with precision from these data, but such interventions may be more effective when initiated in midlife than at a more advanced age.

Acknowledgements

Data in this article were collected by the Multicenter AIDS Cohort Study (MACS) with centers at Baltimore (U01-AI35042): The Johns Hopkins University, Bloomberg School of Public Health: Joseph B. Margolick (PI), Todd Brown (PI), Jay Bream, Adrian Dobs, Michelle Estrella, W. David Hardy, Lisette Johnson-Hill, Sean Leng, Anne Monroe, Cynthia Munro, Michael W. Plankey, Wendy Post, Ned Sacktor, Jennifer Schrack, Chloe Thio; Chicago (U01-AI35039): Feinberg School of Medicine, Northwestern University and Cook County Bureau of Health Services: Steven M. Wolinsky (PI), Sheila Badri, Dana Gabuzda, Frank J. Palella, Jr., Sudhir Penugonda, John P. Phair, Susheel Reddy, Matthew Stephens, Linda Teplin; Los Angeles (U01-AI35040): University of California, UCLA Schools of Public Health and Medicine: Roger Detels (PI), Otoniel Martínez-Maza (PI), Otto Yang (Co-PI), Peter Anton, Robert Bolan, Elizabeth Breen, Anthony Butch, Shehnaz Hussain, Beth Jamieson, John Oishi, Harry Vinters, Dorothy Wiley, Mallory Witt, Stephen Young, Zuo Feng Zhang; Pittsburgh (U01-AI35041): University of Pittsburgh, Graduate School of Public Health: Charles R. Rinaldo (PI), Lawrence A. Kingsley (PI), Jeremy J. Martinson (PI), James T. Becker, Phalguni Gupta, Kenneth Ho, Susan Koletar, John W. Mellors, Anthony J. Silvestre, Ronald D. Stall; Data Coordinating Center (UM1-AI35043): The Johns Hopkins University Bloomberg School of Public Health: Lisa P. Jacobson (PI), Gypsyamber D'Souza (PI), Alison Abraham, Keri Althoff, Michael Collaco, Priya Duggal, Sabina Haberlen, Eithne Keelaghan, Heather McKay, Alvaro Muñoz, Derek Ng, Anne Rostich, Eric C. Seaberg, Sol Su, Pamela Surkan, Nicholas Wada. Institute of Allergy and Infectious Diseases: Robin E. Huebner; National Cancer Institute: Geraldina Dominguez. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional cofunding from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Deafness and Communication Disorders (NIDCD). MACS data collection is also supported by UL1-TR001079 (JHU ICTR) from the National Center for Advancing Translational Sciences

(NCATS), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH), Johns Hopkins ICTR or NCATS. The MACS website is located at <http://aidscohortstudy.org/>. T.T.B. was supported in part by K24 AI120834. J.E.L. is supported in part by K23 AI110532.

Author contribution: J.Y., T.T.B., L.P.J. and N.C.S. were involved in the study conception, design, implementation and writing of the article. J.Y. conducted the statistical analyses. J.T.B., A.L., E.M.M., C.A.M., F.J.P. and J.E.L. were involved in significant editing of the article. All authors approved the final version of the article.

Conflicts of interest

T.T.B. has served as a consultant to Gilead Sciences, Merck, Theratechnologies and EMD Serono. F.J.P. has served as a consultant and/or speaker for Gilead Sciences, Janssen Pharmaceuticals, Merck and Co. and Viiv. J.E.L. has served as a consultant to Merck and Gilead Sciences and receives research support from Gilead. All other authors have no conflicts of interests to disclose.

References

1. Mahy M, Autenrieth CS, Stanecki K, Wynd S. **Increasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey data.** *AIDS* 2014; **28** (Suppl 4): S453–S459.
2. Al-Khindi T, Zakzanis KK, van Gorp WG. **Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature.** *J Int Neuropsychol Soc* 2011; **17**:956–969.
3. Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, et al. **Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.** *J Acquir Immune Defic Syndr* 2006; **41**:332–337.
4. Tozzi V, Balestra P, Galgani S, Narciso P, Sampaolesi A, Antinori A, et al. **Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years.** *J Acquir Immune Defic Syndr* 2001; **28**:19–27.
5. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, et al. **Human immunodeficiency virus-associated dementia: an evolving disease.** *J Neuroviral* 2003; **9**:205–221.
6. Mindt MR, Miranda C, Arentoft A, Byrd D, Monzones J, Fuentes A, et al. **Aging and HIV/AIDS: neurocognitive implications for older HIV-positive Latina/o adults.** *Behav Med* 2014; **40**: 116–123.
7. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. **HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy.** *Neurology* 2010; **75**:2087–2096.
8. Marra CM. **HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?** *Antivir Ther* 2015; **20**:365–367.
9. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE. **A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection.** *Neuron* 2009; **64**:133–145.
10. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. **Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.** *Arch Intern Med* 2005; **165**:1179–1184.

11. Vance DE, Fazeli PL, Dodson JE, Ackerman M, Talley M, Appel SJ. **The synergistic effects of HIV, diabetes, and aging on cognition: implications for practice and research.** *J Neurosci Nurs* 2014; **46**:292–305.
12. Sadanand S, Balachandrar R, Bharath S. **Memory and executive functions in persons with type 2 diabetes: a meta-analysis.** *Diabetes Metab Res Rev* 2016; **32**:132–142.
13. Vincent C, Hall PA. **Executive function in adults with type 2 diabetes: a meta-analytic review.** *Psychosom Med* 2015; **77**:631–642.
14. Palta P, Schneider AL, Biessels GJ, Touradji P, Hill-Briggs F. **Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains.** *J Int Neuropsychol Soc* 2014; **20**:278–291.
15. Ma F, Wu T, Miao R, Xiao YY, Zhang W, Huang G. **Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up.** *J Alzheimers Dis* 2015; **43**:1441–1449.
16. Gao Y, Xiao Y, Miao R, Zhao J, Zhang W, Huang G, et al. **The characteristic of cognitive function in type 2 diabetes mellitus.** *Diabetes Res Clin Pract* 2015; **109**:299–305.
17. Cheng G, Huang C, Deng H, Wang H. **Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies.** *Intern Med J* 2012; **42**:484–491.
18. Awad N, Gagnon M, Messier C. **The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function.** *J Clin Exp Neuropsychol* 2004; **26**:1044–1080.
19. Kodl CT, Seaquist ER. **Cognitive dysfunction and diabetes mellitus.** *Endocr Rev* 2008; **29**:494–511.
20. Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, et al. **Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia.** *Arch Neurol* 2012; **69**:1170–1175.
21. Wu Q, Tchetgen Tchetgen EJ, Osypuk T, Weuve J, White K, Mujahid M, et al. **Estimating the cognitive effects of prevalent diabetes, recent onset diabetes, and the duration of diabetes among older adults.** *Dement Geriatr Cogn Disord* 2015; **39**:239–249.
22. West RK, Ravona-Springer R, Schmeidler J, Leroith D, Koifman K, Guerrero-Berroa E, et al. **The association of duration of type 2 diabetes with cognitive performance is modulated by long-term glycemic control.** *Am J Geriatr Psychiatry* 2014; **22**:1055–1059.
23. Cheng C, Lin CH, Tsai YW, Tsai CJ, Chou PH, Lan TH. **Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis.** *J Gerontol A Biol Sci Med Sci* 2014; **69**:1299–1305.
24. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperli T, et al. **Effects of insulin therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2.** *J Neurol Sci* 2010; **288**:112–116.
25. Ravona-Springer R, Heymann A, Schmeidler J, Moshier E, Godbold J, Sano M, et al. **Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes.** *PLoS One* 2014; **9**:e97384.
26. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, et al. **Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial.** *Diabetes Care* 2009; **32**:221–226.
27. Center for Diseases Control and Prevention. National diabetes statistics report 2017. Available at <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf>, [Accessed 27 June 2018].
28. Vance DE, Rubin LH, Valcour V, Waldrop-Valverde D, Maki PM. **Aging and neurocognitive functioning in HIV-infected women: a review of the literature involving the Women's Interagency HIV Study.** *Curr HIV/AIDS Rep* 2016; **13**:399–411.
29. Valcour VG, Shikuma CM, Shiramizu BT, Williams AE, Watters MR, Poff PW, et al. **Diabetes, insulin resistance, and dementia among HIV-1-infected patients.** *J Acquir Immune Defic Syndr* 2005; **38**:31–36.
30. Valcour V. **Insulin resistance and cognition among HIV-infected and HIV-uninfected adult women: the Women's Interagency HIV Study.** *AIDS Res Hum Retroviruses* 2012; **28**:447–453.
31. Valcour V, Rubin LH, Tien P, Anastos K, Young M, Mack W, et al. **Human immunodeficiency virus (HIV) modulates the associations between insulin resistance and cognition in the current combination antiretroviral therapy (cART) era: a study of the Women's Interagency HIV Study (WIHS).** *J Neurovirol* 2015; **21**:415–421.
32. Valcour VG, Sacktor NC, Paul RH, Watters MR, Selnes OA, Shiramizu BT, et al. **Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging With HIV Cohort.** *J Acquir Immune Defic Syndr* 2006; **43**:405–410.
33. Cole MA. **Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals.** *Neurology* 2007; **69**:2213–2220.
34. Sacktor N. **Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus.** *J Neurovirol* 2010; **16**:335–341.
35. Becker JT, Kingsley LA, Molsberry S, Reynolds S, Aronow A, Levine AJ, et al. **Cohort profile: recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study.** *Int J Epidemiol* 2015; **44**:1506–1516.
36. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. **The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.** *Am J Epidemiol* 1987; **126**:310–318.
37. Kingsley LA, Detels R, Kaslow R, Polk BF, Rinaldo CR Jr, Chmiel J, et al. **Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study.** *Lancet* 1987; **1**:345–349.
38. Silvestre AJ, Hylton JB, Johnson LM, Houston C, Witt M, Jacobson L, et al. **Recruiting minority men who have sex with men for HIV research: results from a 4-city campaign.** *Am J Public Health* 2006; **96**:1020–1027.
39. Schenker EL, Hultin LE, Bauer KD, Ferbas J, Margolick JB, Giorgi JV. **Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program.** *Cytometry* 1993; **14**:307–317.
40. Benedict RH, Smerbeck A, Parikh R, Rodgers J, Cadavid D, Erlanger D. **Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials.** *Mult Scler* 2012; **18**:1320–1325.
41. Tombaugh TN. **Trail Making Test A and B: normative data stratified by age and education.** *Arch Clin Neuropsychol* 2004; **19**:203–214.
42. Ratcliff G, Dodge H, Birzescu M, Ganguli M. **Tracking cognitive functioning over time: ten-year longitudinal data from a community-based study.** *Appl Neuropsychol* 2003; **10**:76–88.
43. Sheridan LK, Fitzgerald HE, Adams KM, Nigg JT, Martel MM, Putterli LI, et al. **Normative Symbol Digit Modalities Test performance in a community-based sample.** *Arch Clin Neuropsychol* 2006; **21**:23–28.
44. Matthews CG, Klove K. *Instruction manual for the adult neuropsychology test battery.* Madison, WI: University of Wisconsin Medical School; 1964.
45. Miller EN, Selnes OA, McArthur JC, Satz P, Becker JT, Cohen BA, et al. **Neuropsychological performance in HIV-1-infected homosexual men: the Multicenter AIDS Cohort Study (MACS).** *Neurology* 1990; **40**:197–203.
46. Bennett-Levy J. **Determinants of performance on the Rey-Osterrieth Complex Figure Test: an analysis, and a new technique for single-case assessment.** *Br J Clin Psychol* 1984; **23** (Pt 2):109–119.
47. Lansbergen MM, Kenemans JL, van Engeland H. **Stroop interference and attention-deficit/hyperactivity disorder: a review and meta-analysis.** *Neuropsychology* 2007; **21**:251–262.
48. Miller EN, Satz P, Visscher B. **Computerized and conventional neuropsychological assessment of HIV-1-infected homosexual men.** *Neurology* 1991; **41**:1608–1616.
49. Selnes OA, Miller EN. *Development of a screening battery for HIV-related cognitive impairment: the MACS experience.* New York: Oxford University Press; 1994.
50. Brands AM, Van den Berg E, Manschot SM, Biessels GJ, Kappelle LJ, De Haan EH, et al. **A detailed profile of cognitive dysfunction and its relation to psychological distress in patients with type 2 diabetes mellitus.** *J Int Neuropsychol Soc* 2007; **13**:288–297.
51. Cosway R, Strachan MW, Dougall A, Frier BM, Deary IJ. **Cognitive function and information processing in type 2 diabetes.** *Diabet Med* 2001; **18**:803–810.

52. Ryan CM, Geckle MO. **Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes.** *Diabetes Care* 2000; **23**:1486–1493.
53. Vanhanen M, Koivisto K, Kuusisto J, Mykkanen L, Helkala EL, Hanninen T, *et al.* **Cognitive function in an elderly population with persistent impaired glucose tolerance.** *Diabetes Care* 1998; **21**:398–402.
54. Vanhanen M, Koivisto K, Karjalainen L, Helkala EL, Laakso M, Soininen H, *et al.* **Risk for noninsulin-dependent diabetes in the normoglycaemic elderly is associated with impaired cognitive function.** *Neuroreport* 1997; **8**:1527–1530.
55. Yeung SE, Fischer AL, Dixon RA. **Exploring effects of type 2 diabetes on cognitive functioning in older adults.** *Neuropsychology* 2009; **23**:1–9.
56. Nooyens AC, Baan CA, Spijkerman AM, Verschuren WM. **Type 2 diabetes and cognitive decline in middle-aged men and women: the Doetinchem Cohort Study.** *Diabetes Care* 2010; **33**:1964–1969.
57. van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ. **Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition.** *Biochim Biophys Acta* 2009; **1792**:470–481.
58. Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E. **Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women.** *J Nutr Health Aging* 2006; **10**:293–295.
59. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, *et al.* **Association of duration and severity of diabetes mellitus with mild cognitive impairment.** *Arch Neurol* 2008; **65**:1066–1073.
60. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A. **Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study.** *Diabetes Care* 2001; **24**:366–370.
61. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. **Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort.** *Arch Intern Med* 2004; **164**:1327–1333.
62. Sims Wright R, Levy SA, Katznel LI, Rosenberger WF, Manukyan Z, Whitfield KE, *et al.* **Fasting glucose and glucose tolerance as potential predictors of neurocognitive function among non-diabetic older adults.** *J Clin Exp Neuropsychol* 2015; **37**:49–60.
63. Samaras K, Lutgers HL, Kochan NA, Crawford JD, Campbell LV, Wen W, *et al.* **The impact of glucose disorders on cognition and brain volumes in the elderly: the Sydney Memory and Ageing Study.** *Age (Dordr)* 2014; **36**:977–993.
64. Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Floel A. **Higher glucose levels associated with lower memory and reduced hippocampal microstructure.** *Neurology* 2013; **81**:1746–1752.
65. Di Bonito P, Di Fraia L, Di Gennaro L, Vitale A, Lapenta M, Scala A, *et al.* **Impact of impaired fasting glucose and other metabolic factors on cognitive function in elderly people.** *Nutr Metab Cardiovasc Dis* 2007; **17**:203–208.
66. Euser SM, Sattar N, Witterman JC, Bollen EL, Sijbrands EJ, Hofman A, *et al.* **A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study.** *Diabetes* 2010; **59**:1601–1607.
67. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. **Diabetes, impaired fasting glucose, and development of cognitive impairment in older women.** *Neurology* 2004; **63**:658–663.
68. Ellis RJ. **CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.** *AIDS* 2011; **25**:1747–1751.
69. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, *et al.* **HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.** *J Neurovirol* 2011; **17**:3–16.
70. Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbatecola AM, *et al.* **Insulin resistance in cognitive impairment: the InCHIANTI study.** *Arch Neurol* 2005; **62**:1067–1072.
71. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. **Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men.** *Diabetologia* 1995; **38**:1096–1102.
72. Luchsinger JA. **Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective.** *Eur J Pharmacol* 2008; **585**:119–129.
73. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, *et al.* **Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance.** *Neurology* 1999; **52**:971–975.
74. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, *et al.* **Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study.** *Neurology* 1995; **45**:1161–1168.
75. Peila R, Rodriguez BL, Launer LJ. **Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study.** *Diabetes* 2002; **51**:1256–1262.
76. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, *et al.* **The risk of dementia among persons with diabetes mellitus: a population-based cohort study.** *Ann N Y Acad Sci* 1997; **826**:422–427.
77. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, *et al.* **Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study.** *BMJ* 1997; **315**:1045–1049.
78. Craft S, Watson GS. **Insulin and neurodegenerative disease: shared and specific mechanisms.** *Lancet Neurol* 2004; **3**:169–178.
79. Brownlee M. **The pathobiology of diabetic complications: a unifying mechanism.** *Diabetes* 2005; **54**:1615–1625.
80. Klein JP, Waxman SG. **The brain in diabetes: molecular changes in neurons and their implications for end-organ damage.** *Lancet Neurol* 2003; **2**:548–554.
81. Toth C, Schmidt AM, Tuor UI, Francis G, Foniok T, Brussee V, *et al.* **Diabetes, leukoencephalopathy and rage.** *Neurobiol Dis* 2006; **23**:445–461.
82. Yamamoto N, Yamanaka G, Takasugi E, Ishikawa M, Yamanaka T, Murakami S, *et al.* **Lifestyle intervention reversed cognitive function in aged people with diabetes mellitus: two-year follow up.** *Diabetes Res Clin Pract* 2009; **85**:343–346.
83. Ritchie K, Carriere I, Ritchie CW, Berr C, Artero S, Ancelin ML. **Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors.** *BMJ* 2010; **341**:c3885.
84. Bourdel-Marchasson I, Lapre E, Laksir H, Puget E. **Insulin resistance, diabetes and cognitive function: consequences for preventive strategies.** *Diabetes Metab* 2010; **36**:173–181.